Skip to main content
Premium Trial:

Request an Annual Quote

James Glover Leaves Beckman Coulter; Thermo s CEO to Pocket $1.3M Bonus; James Glynn Says Good-Bye to Invitrogen; Donald Grimm Joins HTG Board; Peter Ellman Replaces David Tholen on Stratagene Board; and others

James Glover is retiring from Beckman Coulter as senior vice president and chief financial officer, the company announced last week.

 

The company has started a search to replace him.


James Glynn is retiring from Invitrogen's board on April 21, the company said last week.

 

Glynn has served the company for almost 10 years and retires as chief executive emeritus.

 

Invitrogen said that there will be only nine directors after Glynn's departure.


Donald Grimm was named a director of HTG, the array-based gene-expression company said yesterday.

 

Grimm is a partner at Hamilton BioVentures. He has served on the boards of Aegis Therapeutics, Angstrom Pharmaceuticals, CellzDirect, and Invitrogen. He has held managerial positions at Eli Lilly and served as president and CEO of Hybritech.


Stratagene said last week that David Tholen is retiring from the company's board and that Peter Ellman has been named a director.

 

Ellman is the founder of The Raisin Group management consulting group. Prior to that, he was CEO of Nextec Applications.


Sirna Therapeutics has named Lutz Lingnau a director and elevated director Scott Greer to chairman of the board, the RNAi company said last week.

 

Lingnau was an executive board member at Schering AG. He was also president and CEO of Berlex Laboratories.

 

Greer has been on Sirn'a board for two years. He is also the chairman of the board of Abgenix and Acologix and has served on the boards of CV Therapeutics and Illumina. He is managing director of Numenor Ventures.


George Uveges was named a director of Harvard Biosciences, the company said yesterday.

 

His appointment is effective as of the day after the company files its annual report. He will serve on the audit committee, the company said.

 

Uveges is the founder of the Tallwood Group. He is the former president and CEO of TranXenoGen, and was a director of that company from 2001 to 2005. He has also held executive positions at BioSource, NEN Life Science, Gelman Sciences, GI Plastek and Invacare.


Exagen named Thomas Williams chief science officer and vice president, research and development, the company said yesterday.

 

Williams was Exagen's special advisor for molecular pathology before joining the company full time. He is a part-time professor of pathology at the University of New Mexico, where he is the former vice chairman of the department of pathology.


David Patteson is stepping down as president of Biotage's discovery chemistry division as of April 1, the company announced last week.

 

He leaves to "seek new challenges elsewhere," according to a statement from the company.

 

Torben Jorgensen will succeed Patteson.


Thermo Electron is paying chief executive Marijn Dekkers a bonus of more than $1.3 million, according to regulatory filings last week. Dekkers'   2006 salary is just over $1 million, the filing said.


Heidelberg, Germany-based Lion Bioscience named Werner Hacke to the company's supervisory board, Lion said last week.

 

Hacke succeeds Christoph Mutter.

 

Hacke is the director of the Neurologische Klinik of the University of Heidelberg since 1987. He also is a supervisor of the SRH Kliniken in Heidelberg.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.